Donor 'Memory' immune cells take on childhood cancer

NCT ID NCT07635056

Recruiting now Disease control Sponsor: Children's Hospital Medical Center, Cincinnati Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether specially trained donor immune cells, called CIML-NK cells, can be safely given to 20 children and young adults (ages 1-39) with relapsed or refractory neuroblastoma. The cells are made from a half-matched donor and infused alongside standard dinutuximab therapy. The main goal is to check for serious side effects, while also seeing if the treatment can shrink tumors or stabilize the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cytokine-Induced Memory-Like Natural Killer (CIML-NK) cells from a half-matched donor
What this could lead to: If it works, this could offer a new treatment option for children and young adults with neuroblastoma that has come back or not responded to standard therapy.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The cell therapy carries risks of infusion reactions and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA

Contacts and locations

Locations

Cincinnati Children's Hospital Medical Center
RECRUITING

Cincinnati, Ohio, 45229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.